MedDataX Logo

Continous Assessment of Cerebral Autoregulation With Near-infrared Spectroscopy

NCT ID: NCT02959008

Last Updated: 2016-11-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-12-31

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cerebral autoregulation can be explained by a tight coupling between oxygen supply and demand of the brain, and is essential to maintain a constant cerebral blood flow (CBF) in the context of changes in cerebral perfusion pressure. In this study, investigators use Near-infrared spectroscopy (NIRS) to monitor cerebral autoregulation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Near-infrared spectroscopy (NIRS) is a noninvasive technology that real-time monitors cerebral tissue oxygenation index (TOI). Investigators use Near-infrared spectroscopy (NIRS) to monitor cerebral autoregulation of hypertensive participants and non-hypertensive participants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Blood Flow Cerebral Perfusion Pressure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

normal

Human without hypertension, diabetes, anemia, liver disease and kidney disease. The group will measure TOI and BP.

measure TOI and BP

Intervention Type DEVICE

Both groups measure TOI and BP.

hypertension

Human only have hypertension, without diabetes, anemia, liver disease and kidney disease.

Hypertension group will measure TOI and BP.

measure TOI and BP

Intervention Type DEVICE

Both groups measure TOI and BP.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

measure TOI and BP

Both groups measure TOI and BP.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* health people, or people with hypertension

Exclusion Criteria

* diabetes, anemia, liver disease, kidney disease.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yu Liyun

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yu Liyun

Principal Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xiaohong Wu

Role: PRINCIPAL_INVESTIGATOR

Beijing Electric Power Hospital

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Liyun Yu

Role: CONTACT

Phone: 13683217693

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

111

Identifier Type: -

Identifier Source: org_study_id